Arcus Biosciences, Inc. (NYSE:RCUS) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Arcus Biosciences, Inc. (NYSE:RCUS) have been assigned a consensus rating of “Moderate Buy” from the eleven research firms that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $30.00.

RCUS has been the topic of several analyst reports. Citigroup reaffirmed a “buy” rating on shares of Arcus Biosciences in a research report on Friday, December 12th. Wedbush set a $35.00 target price on shares of Arcus Biosciences and gave the company an “outperform” rating in a report on Wednesday, October 29th. Wall Street Zen downgraded shares of Arcus Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday. Truist Financial set a $30.00 price target on Arcus Biosciences in a research report on Friday, December 12th. Finally, UBS Group restated a “buy” rating on shares of Arcus Biosciences in a research note on Monday, December 15th.

Arcus Biosciences Trading Up 0.5%

Shares of Arcus Biosciences stock opened at $21.13 on Tuesday. Arcus Biosciences has a 12-month low of $6.50 and a 12-month high of $26.40. The stock has a market cap of $2.28 billion, a P/E ratio of -6.14 and a beta of 0.84. The company has a quick ratio of 3.65, a current ratio of 3.65 and a debt-to-equity ratio of 0.22. The business’s 50 day moving average is $22.75 and its 200-day moving average is $17.55.

Insiders Place Their Bets

In other Arcus Biosciences news, CAO Alexander Azoy sold 4,343 shares of the company’s stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $22.25, for a total value of $96,631.75. Following the transaction, the chief accounting officer directly owned 18,531 shares in the company, valued at $412,314.75. The trade was a 18.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, President Juan C. Jaen sold 31,823 shares of the firm’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $21.41, for a total transaction of $681,330.43. Following the sale, the president owned 922,240 shares of the company’s stock, valued at approximately $19,745,158.40. This represents a 3.34% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 315,887 shares of company stock worth $7,087,692 in the last quarter. Company insiders own 9.60% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. AQR Capital Management LLC lifted its position in Arcus Biosciences by 253.9% during the first quarter. AQR Capital Management LLC now owns 90,954 shares of the company’s stock worth $714,000 after acquiring an additional 65,254 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Arcus Biosciences by 10.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,572 shares of the company’s stock worth $297,000 after purchasing an additional 3,565 shares during the period. Millennium Management LLC lifted its holdings in Arcus Biosciences by 29.2% during the 1st quarter. Millennium Management LLC now owns 1,194,622 shares of the company’s stock worth $9,378,000 after purchasing an additional 270,253 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in Arcus Biosciences by 106.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 914,208 shares of the company’s stock worth $7,177,000 after purchasing an additional 470,755 shares during the last quarter. Finally, Strs Ohio bought a new stake in Arcus Biosciences in the 1st quarter valued at $67,000. Institutional investors and hedge funds own 92.89% of the company’s stock.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.